お知らせ :東京証券取引所JASDAQスタンダード市場への新規上場に関するお知らせ

株式会社グローバルインフォメーション
表紙
市場調査レポート
商品コード
973883

敗血症診断の世界市場:アッセイ、原因別 - エグゼクティブおよびコンサルタントガイドとCOVID-19関連の敗血症 - 2020年~2025年の予測

Sepsis Diagnostics Global Markets by Assay & Cause with Executive and Consultant Guides and COVID-19 Related Sepsis Market Analysis and Forecasts 2020 - 2025

出版日: | 発行: Howe Sound Research | ページ情報: 英文 356 Pages | 納期: 即日から翌営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=104.77円
敗血症診断の世界市場:アッセイ、原因別 - エグゼクティブおよびコンサルタントガイドとCOVID-19関連の敗血症 - 2020年~2025年の予測
出版日: 2020年12月01日
発行: Howe Sound Research
ページ情報: 英文 356 Pages
納期: 即日から翌営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

当レポートは、敗血症診断市場について調査しており、市場規模・予測、技術開発、成長および抑制要因、アッセイタイプ・原因・地域別の市場分析、競合情勢、主要企業のプロファイルなどの情報を提供しています。

目次

マーケットガイド

  • 状況分析:COVID・敗血症
  • エグゼクティブ・マーケティングスタッフのためのガイド
  • 投資アナリスト・経営コンサルタントのためのガイド

第1章 イントロダクションと市場の定義

  • 敗血症診断の概要
    • 医療緊急事態を敗血症
    • 敗血症の診断と併存症
  • 市場の定義
  • 調査手法
  • 米国の医療市場と臨床検査:展望
    • 臨床検査のための米国のメディケア支出

第2章 敗血症:現在の科学

  • 敗血症とは何か?
    • 臓器障害
    • 新生児敗血症
    • 予後
  • 診断
    • 感染の識別
    • バイオマーカー
    • 鑑別診断
    • サイトカインストーム:診断の必要性
  • 敗血症の原因
    • 敗血症の進行
    • サイトカインストーム:COVIDおよびその他の状況
  • 有病率
    • 敗血症の有病率に対するCOVIDの影響

第3章 業界の概要

  • 市場参入企業
    • 学術調査ラボ
    • 診断検査開発者
    • 医薬品/試薬サプライヤー
    • 独立した検査ラボ
    • 公立国立/地域研究所
    • 病院ラボ
    • 医師ラボ
    • 監査機関
    • 認証機関

第4章 市場動向

  • 成長要因
    • 有病率の増加
    • 抗菌剤耐性
    • 診断の増加
    • マルチプレックス診断の影響
    • 世界における高齢化
    • COVID市場への影響
  • 抑制要因
    • 市場を縮小させるコスト曲線
    • 診断のジレンマ
    • 採用の遅れとコスト管理
  • 診断技術の開発
    • マルチプレックスの機会
    • 診断における医師の役割の変化
    • 診断がラボから移動
    • バイオマーカーとアルゴリズム
    • 医療行為を変える迅速な検査
    • ゲノムの役割とビッグデータ
    • 今後5年間

第5章 敗血症の診断:最近の進展

  • 最近の開発-重要性とこのセクションの使用方法
    • これらの開発の重要性
    • このセクションの使用方法
    • SpeeDx:呼吸器ウイルスの宿主応答検査の開発
    • Scanogen:敗血症アプリケーションを使用した血液感染検査の開発
    • Inflammatix:COVID検査市場への参入
    • Immunexpress:コロナウイルス患者トリアージの敗血症検査の開発
    • ポータブルデバイスによる敗血症のより速い診断
    • OnteraとQuantuMDxの協力による敗血症診断
    • 血液検査による敗血症の重症度の正確な予測
    • マルチマーカーを使用した形態学的発達敗血症検査、など

第6章 主要企業のプロファイル

  • Abbott Diagnostics
  • Abionic
  • Accel Diagnostics
  • Accelerate Diagnostics
  • Axis-Shield Diagnostics Ltd
  • Beckman Coulter, Inc.
  • Becton, Dickinson and Company
  • Biocartis
  • bioMérieux Diagnostics
  • Bio-Rad Laboratories, Inc.
  • Bruker
  • Cube Dx
  • Curetis N.V. / Curetis GmbH
  • Cytovale
  • EKF Diagnostics Holdings
  • GeneFluidics
  • GenMark Dx
  • Grifols
  • Immunexpress
  • Inflammatix
  • Linear Diagnostics
  • Luminex Corp
  • Mbio Diagnostics
  • Mobidiag
  • Nanomix
  • Qiagen Gmbh
  • Response Biomedical
  • Roche Molecular Diagnostics
  • SeLux Diagnostics
  • Septec
  • Siemens Healthineers
  • Sphingotec
  • T2 Biosystems
  • Thermo Fisher Scientific Inc

第7章 敗血症診断市場

  • 国別:世界の市場概要
    • チャート

第8章 市場分析:アッセイタイプ別

  • 世界市場の概要
  • 微生物
  • 症候群PoCパネル
  • その他の感染症
  • バイオマーカー分子診断
  • その他のバイオマーカー

第9章 市場分析:原因別

  • 世界市場の概要
  • 胃腸
  • 呼吸器(COVID-19)
  • 呼吸器(その他)
  • 新生児
  • その他

付録

  • 米国のメディケアシステム:2020年の臨床検査料金スケジュール
図表

Table of Tables

  • Table 1: Lab Spending 2014 to 2024
  • Table 2: sepsis biomarkers - Established and potential
  • Table 3: Market Players by Type
  • Table 4: Five Factors Driving Growth
  • Table 5: Three Factors Limiting Growth
  • Table 6: - Global Sepsis Diagnostics Market by Country/Region
  • Table 7: Global Market by Assay Type
  • Table 8: Sepsis Diagnostic Microbiology by Country
  • Table 9: Sepsis Diagnostic Syndromic PoC Panel by Country
  • Table 10: Sepsis Diagnostic Other ID by Country
  • Table 11: Sepsis Diagnostic Biomarker MDx by Country
  • Table 12: Sepsis Diagnostic Biomarker Other by Country
  • Table 13: Global Market by Cause
  • Table 14: Sepsis Diagnostic GastroIntestinal by Country
  • Table 15: Sepsis Diagnostic Respiratory COVID-19 by Country
  • Table 16: Sepsis Diagnostic Respiratory Other by Country
  • Table 17: Sepsis Diagnostic Newborn by Country
  • Table 18: Sepsis Diagnostic Other Cause by Country
  • Table 19: 2020 Clinical Lab Fee Schedule

Table of Figures

  • Figure 1: Sepsis Survival graph
  • Figure 2: Percentage of Sepsis Patients with Comorbidity
  • Figure 3: Clinical Lab Spending 2014 to 2024
  • Figure 4: Sepsis Clinical Progression
  • Figure 5: Deaths From Drug Resistant Infections 2050
  • Figure 6: Aggregate Age of World Population
  • Figure 7: Growth in Health Care Spending Developing World
  • Figure 8: Comparing The New Diagnostics and Traditional Testing
  • Figure 9: Growth rates of Sepsis Diagnostics
  • Figure 10: Global Market Share Chart
  • Figure 11: Sepsis Diagnostics Market Segment Shift Base vs Final year
  • Figure 12: Sepsis Diagnostics Market by Type Base Year
  • Figure 13: Sepsis Diagnostics Market by Type Final Year
  • Figure 14: Type Share by Year
  • Figure 15: Sepsis Diagnostic Microbiology Growth
  • Figure 16: SEPSIS DIAGNOSTICS Syndromic POC Panel Growth
  • Figure 17: Sepsis Diagnostic Other Infectious Disease Growth
  • Figure 18: Sepsis Diagnostic Molecular Diagnostics Growth
  • Figure 19: Sepsis Diagnostic Biomarker Other Growth
  • Figure 20: Sepsis Diagnostics Market Cause Segment Shift Base vs Final year
  • Figure 21: Sepsis Diagnostics by Cause Segment Base Year
  • Figure 22: Sepsis Diagnostics Market by Cause Segment Final Year
  • Figure 23: Cause Share by Year
  • Figure 24: Sepsis Diagnostic GastroIntestinal Growth
  • Figure 25: SEPSIS DIAGNOSTICS Respiratory COVID-19
  • Figure 26: Sepsis Diagnostic Respiratory Other Growth
  • Figure 27: Sepsis Diagnostic Newborn Growth
  • Figure 28: Sepsis Diagnostic Other Cause Growth
目次

OVERVIEW:

Sepsis was killing over 30 million people a year with no definitive diagnostic in hand. And now the COVID Pandemic has increased the sepsis death toll. The race is on using all the genomic and molecular diagnostic tools that have come to the fore in the last decade. It is not clear who will be the winner, but the stakes are global and large. Emergency life saving diagnostics can command a premium in the market, especially deaths related to COVID infections. Understand the different drivers of this huge global diagnostic market and where the opportunity lies.

Our facts and support = Your success.

The report forecasts the market size out to 2025. Growth is coming from the basic factors but the COVID Pandemic has changed to market landscape now and for the foreseeable future. Some players have already made their mark but disruptive diagnostic technology could change the playing field. Learn about this market including the issues and outlooks. The two key trends of Rapid Diagnositic and the Genomics Revolution are merging to create new diagnostic opportunities.

All report data is available in Excel format on request.

Make investment decisions and valuations with confidence using the latest data.

ABOUT THE LEAD AUTHOR:

Mr. Greg Powell, B.SC., M.B.A is the President of Howe Sound Research. He is an experienced business and clinical professional. He is co-author of the paper "The Radioimmunoassay of Angiotensinogen by Antibody Trapping." He has worked in laboratory testing and management for over 20 years. Mr. Powell's education includes:

  • B.Sc. (Chemistry) University of BC
  • M.B.A. (Finance and Policy) University of BC
  • Market Research Seminar - Burke Institute
  • Finance for Senior Executives - Harvard Business School

Table of Contents

i. Market Guides

  • iA. Situation Analysis - COVID & Sepsis
  • iB. Guide for Executives and Marketing Staff
  • iC. Guide for Investment Analysts and Management Consultants

1. Introduction and Market Definition

  • 1.1. An Overview of Sepsis Diagnostics
    • 1.1.1. Sepsis the medical emergency
    • 1.1.2. Sepsis Diagnosis and Comorbidity
  • 1.3. Market Definition
    • 1.3.1. Market Size
    • 1.3.2. Currency
    • 1.3.3. Years
    • 1.3.4. Microbiology
    • 1.3.5. Other Infectious Disease
    • 1.3.6. Syndromic PoC
    • 1.3.7. Biomarkers Molecular Diagnostics
    • 1.3.8. Biomarkers Other
    • 1.3.9. Limitations
  • 1.4. Methodology
    • 1.4.1. Authors
    • 1.4.2. Sources
  • 1.5. U.S. Medical Market and laboratory Testing - Perspective
    • 1.4.1. U.S. Medicare Expenditures for Laboratory Testing

2. Sepsis - Current Science

  • 2.1. What is Sepsis?
    • 2.1.1. Organ Damage
    • 2.1.2. Neonatal sepsis
    • 2.1.3. Prognosis
  • 2.2. Diagnosis
    • 2.2.1. Infection Identification
    • 2.2.2. Biomarkers
    • 2.2.3. Differential diagnosis
    • 2.2.4. The Cytokine Storm - Diagnostic Needs
  • 2.3. Causes of Sepsis
    • 2.3.1. Sepsis Progression
    • 2.3.2. The Cytokine Storm - COVID and Other Situations
  • 2.4. Prevalence
    • 2.4.1. Impact of COVID on Sepsis Prevalence

3. Industry Overview

  • 3.1. Players in a Dynamic Market
    • 3.1.1. Academic Research Lab
    • 3.1.2. Diagnostic Test Developer
    • 3.1.3. Pharmaceutical/Reagent Supplier
    • 3.1.4. Independent Testing Lab
    • 3.1.6. Public National/regional lab
    • 3.1.7. Hospital lab
    • 3.1.8. Physician Lab
    • 3.1.9. Audit Body
    • 3.1.10. Certification Body

4. Market Trends

  • 4.1. Factors Driving Growth
    • 4.1.1. Increasing Prevalence
    • 4.1.2. Antimicrobial Resistance
    • 4.1.3. Increasing Diagnosis
    • 4.1.4. Multiplex Diagnostics Impacts
    • 4.1.5. The Aging World
    • 4.1.6. COVID Market Impact
  • 4.2. Factors Limiting Growth
    • 4.2.1. The Cost Curve Shrinks the Market
    • 4.2.2. The Diagnostics Dillemma
    • 4.2.3. Adoption Lag and Cost Control
  • 4.3. Diagnostic Technology Development
    • 4.3.1. The Multiplex Opportunity
    • 4.3.2. Shifting Role of Physicians in Diagnosis
    • 4.3.3. Diagnostics Moves Out of the Lab
    • 4.3.4. Biomarkers and Algorithms
    • 4.3.5. Rapid Testing Changing Medical Practice
    • 4.3.6. Genome Role and Big Data
    • 4.3.6. The Next Five Years

5. Sepsis Diagnostics - Recent Developments

  • 5.1. Recent Developments - Importance and How to Use This Section
    • 5.1.1. Importance of These Developments
    • 5.1.2. How to Use This Section
    • SpeeDx Developing Respiratory Virus Host-Response Test
    • Scanogen Developing Blood Infection Test with Sepsis Application
    • Inflammatix Moving Into COVID Test Market and Developing New Sepsis
    • Immunexpress, Biocartis to Roll Out Sepsis Test
    • Sepset Biosciences Using COVID-19 Patient Samples to Validate Sepsis Test
    • Immunexpress to Develop Sepsis Test for Coronavirus Patient Triage
    • DNAe Developing POC Sequencing Platform for Coronavirus, Sepsis
    • NGS technique offers quick, accurate diagnosis of sepsis
    • Portable device diagnoses sepsis faster
    • Ontera and QuantuMDx Collaborate to Advance Sepsis Diagnosis
    • Blood Test Accurately Predicts Sepsis Severity
    • Sepsis diagnostics: HHS to advance development of Cytovale rapid test
    • Mologic Developing Sepsis Test Using Multimarker
    • Abionic: Study Demonstrates Diagnosis of Sepsis in 5 Minutes
    • T2 Biosystems Introduces New Data and Updates for Rapid Diagnostic Technology
    • Sepsis found to fit into 4 subtypes
    • GenMark Diagnostics Receives FDA Clearance for Blood Panel
    • Novacyt, Immunexpress Extend Sepsis Assay Development Partnership
    • New Test Could Diagnose Sepsis Faster
    • Immunexpress Wins $745K HHS Contract for Rapid Sepsis Assay
    • Curetis' Unyvero Application Cartridges Receive Regulatory Approvals
    • Luminex to Pay $75M for MilliporeSigma's Flow Cytometry Research Portfolio
    • Experimental 2.5-minute Sepsis Test Discovered
    • sphingotec raises €20 million
    • SeLux Diagnostics Announces Sepsi U.S. HHS/BARDA Research Funding
    • Roche PCT assay cleared as tool in fight against Sepsis
    • GeneFluidics selected as finalist for AMR Challenge
    • BioDirection, Inc. Announces System to Diagnose and Monitor Sepsis
    • sphingotec Adding Advanced POC Testing Platform
    • Rapid Detection Using DNAe's LiDia® Bloodstream Infection Technology
    • Septec Team Working on 15 Minute Sepsis Diagnosis
    • Abionic Announces Rapid Sepsis PoC Diagnostic

6. Profiles of Key Companies

  • Abbott Diagnostics
  • Abionic
  • Accel Diagnostics
  • Accelerate Diagnostics
  • Axis-Shield Diagnostics Ltd
  • Beckman Coulter, Inc.
  • Becton, Dickinson and Company
  • Biocartis
  • bioMérieux Diagnostics
  • Bio-Rad Laboratories, Inc.
  • Bruker
  • Cube Dx
  • Curetis N.V. / Curetis GmbH
  • Cytovale
  • EKF Diagnostics Holdings
  • GeneFluidics
  • GenMark Dx
  • Grifols
  • Immunexpress
  • Inflammatix
  • Linear Diagnostics
  • Luminex Corp
  • Mbio Diagnostics
  • Mobidiag
  • Nanomix
  • Qiagen Gmbh
  • Response Biomedical
  • Roche Molecular Diagnostics
  • SeLux Diagnostics
  • Septec
  • Siemens Healthineers
  • Sphingotec
  • T2 Biosystems
  • Thermo Fisher Scientific Inc

7. Sepsis Diagnostic Markets

  • 7.1. Sepsis Diagnostics - Global Market Overview by Country
    • 7.1.1. Table - Global Market by Country
    • 7.1.2. Chart - Global Market by Country

8. Global Sepsis Diagnostics Markets - By Assay Type

  • 8.1. Global Market by Diagnostic Type - Overview
    • 8.1.1. Table - Global Market by Diagnostic Type
    • 8.1.2. Chart - Global Market by Assay Type
    • 8.1.3. Chart - Global Market by Type - Base Year
    • 8.1.4. Chart - Global Market by Type - Final Year
    • 8.1.4. Chart - Global Market by Type - Share by Year
  • 8.2. Sepsis Diagnostic - Microbiology
    • 8.2.1. Table Sepsis Diagnostic Microbiology - by Country
    • 8.2.2. Chart - Sepsis Diagnostic Microbiology Growth
  • 8.3. Sepsis Diagnostic - Syndromic PoC Panel
    • 8.3.1. Table Sepsis Diagnostic Syndromic PoC Panel - by Country
    • 8.3.2. Chart - Sepsis Diagnostic Syndromic PoC Panel Growth
  • 8.4. Sepsis Diagnostic - Other Infectious Disease
    • 8.4.1. Table Sepsis Diagnostic Other ID - by Country
    • 8.4.2. Chart - Sepsis Diagnostic - Other Infectious Disease Growth
  • 8.5. Sepsis Diagnostic - Biomarker Molecular Diagnostic
    • 8.5.1. Table Sepsis Diagnostic Biomarker MDx - by Country
    • 8.5.2. Chart - Sepsis Diagnostic - Biomarker MDx Growth
  • 8.6. Sepsis Diagnostic - Biomarker Other
    • 8.6.1. Table Sepsis Diagnostic Biomarker Other - by Country
    • 8.6.2. Chart - Sepsis Diagnostic - Biomarker Other Growth

9. Global Sepsis Diagnostics Markets - By Cause

  • 9.1. Global Market by Cause - Overview
    • 9.1.1. Table - Global Market by Cause
    • 9.1.2. Chart - Global Market by Cause
    • 9.1.3. Chart - Global Market by Type - Base Year
    • 9.1.4. Chart - Global Market by Type - Final Year
    • 9.1.4. Chart - Global Market by Cause - Share by Year
  • 9.2. Sepsis Diagnostic - GastroIntestinal
    • 9.2.1. Table Sepsis Diagnostic GastroIntestinal - by Country
    • 9.2.2. Chart - Sepsis Diagnostic GastroIntestinal Growth
  • 9.3. Sepsis Diagnostic - Respiratory COVID-19
    • 9.3.1. Table Sepsis Diagnostic Respiratory COVID-19- by Country
    • 9.3.2. Chart - Sepsis Diagnostic Respiratory COVID-19
  • 9.4. Sepsis Diagnostic - Respiratory Other
    • 9.4.1. Table Sepsis Diagnostic Respiratory Other - by Country
    • 9.4.2. Chart - Sepsis Diagnostic - Respiratory Other Growth
  • 9.5. Sepsis Diagnostic - Newborn
    • 9.5.1. Table Sepsis Diagnostic Newborn - by Country
    • 9.5.2. Chart - Sepsis Diagnostic - Newborn Growth
  • 9.6. Sepsis Diagnostic - Other Cause
    • 9.6.1. Table Sepsis Diagnostic Other Cause - by Country
    • 9.6.2. Chart - Sepsis Diagnostic - Other Cause Growth

Appendices

  • I. United States Medicare System: 2020 Clinical Laboratory Fees Schedule
株式会社グローバルインフォメーション
© Copyright 1996-2021, Global Information, Inc. All rights reserved.